Fosun Pharma (600196.SH) subsidiary obtains approval from the US FDA for drug clinical trials.

Uptech Financial News APP News, Fosun Pharma (600196.SH) announced that its controlling subsidiary Shanghai Fuhong Hanlin Biotechnology Co., Ltd. and its subsidiary (collectively referred to as "Fuhong Hanlin") have received approval from the US FDA (Food and Drug Administration) to conduct Phase I clinical trials for injection HLX43 (targeting PD-L1 antibody conjugate drug, referred to as "the new drug") for the treatment of thymic cancer (TC). Fuhong Hanlin intends to conduct global multicenter clinical studies for this indication in Australia, Japan, the United States, and other countries once the conditions are met.